Abbott Laboratories approaches Q3 earnings with 13.5% revenue growth forecast
Question
Abbott Laboratories approaches Q3 earnings with 13.5% revenue growth forecast
Direct answer
Anticipated mid-teens revenue growth of 13.52% supports multiple stability for large-cap healthcare as ABT approaches its October 21 print. — bullish pressure on ABT via operating earnings and revenue expansion into Q3 results.
- Original publisher
- Market Ontology
- Evidence through
- 2026-10-13
- Published
- 2026-10-20
- Revision
- 1 · 2026-10-20
Cite as: Market Ontology, “Abbott Laboratories approaches Q3 earnings with 13.5% revenue growth forecast”, revision 1, evidence through 2026-10-13. https://marketontology.com/catalysts/2026-10-13/abbott-laboratories-approaches-q3-earnings-with-13-5-revenue-growth-forecast-3e1035
| Asset | Direction | Timeframe | Channel | Score |
|---|---|---|---|---|
| ABT | ▲Bull | 1–4 weeks | operating earnings and revenue expansion into Q3 results | 69 |
Abbott Laboratories approaches Q3 earnings with 13.5% revenue growth forecast
Anticipated mid-teens revenue growth of 13.52% supports multiple stability for large-cap healthcare as ABT approaches its October 21 print. — bullish pressure on ABT via operating earnings and revenue expansion into Q3 results.
Projected EPS of $1.42 (+9.23% YoY) and revenue of $12.91B (+13.52% YoY) scheduled for Oct 21.
- SourceProjected EPS of $1.42 (+9.23% YoY) and revenue of $12.91B (+13.52% YoY) scheduled for Oct 21.
- TransmissionAnticipated mid-teens revenue growth of 13.52% supports multiple stability for large-cap healthcare as ABT approaches its October 21 print.
- SummaryAbbott Laboratories gained 2.23% to close at $101.82 against a flat-to-down tape. Consensus expects $1.42 EPS on $12.91 billion in revenue for Q3, up 9.23% and 13.52% year-over-year respectively. Results are scheduled for release on October 21, 2026.
- ABTDirect directional exposure
Illustrative, not advice
- Crowded positioning may already reflect the move
- Counter-catalyst could neutralize the thesis before window closes
- Sector rotation or peer guidance may override single-name reaction
- ABT closes below pre-catalyst level on rising volume
- Catalyst narrative is officially walked back or contradicted
- Cross-asset confirmation (rates / FX / vol) reverses direction
- ABT price vs. pre-event level
- ABT volume vs. 20-day average
- Sector ETF read-through
- Options implied volatility crush
What happened next
Price follow-up pending — no stored daily closes for these assets yet.
Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.
Sources
- Abbott (ABT) Gains As Market Dips: What You Should Know · news · 2026-10-12
Related catalysts
- 2026-10-19Citadel Expands Defensive Healthcare Positions Across AbbVie, Abbott, and Eli LillyABBV ABT LLY SPY
- 2026-10-19Citadel Expands Defensive Healthcare Positions Across AbbVie, Abbott, and Eli LillyABBV ABT LLY
- 2026-10-13Abbott Sets Q3 2026 Earnings Release for October 21 with $12.91B Revenue ForecastABT
- 2026-10-13Abbott and AbbVie Gain Over 1.6% Outperforming S&P on Strong Q3 Growth OutlookABBV ABT
- 2026-10-13Abbott Laboratories Rises 2.2% Ahead of Q3 Results Projecting 13.5% Top-Line GrowthABT IHI XLV+2.53%
- 2026-10-13Abbott Gains 2.23% to $101.82 on Projected 9.2% Q3 EPS Growth to $1.42ABT
- 2026-10-13Abbott Rises 2.23% to $101.82 Ahead of October 21 Q3 Earnings ReleaseABT
- 2026-10-13Abbott and AbbVie Gain Over 1.6% Outperforming S&P on Strong Q3 Growth OutlookABBV ABT
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.